• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双价抗体片段双体的晶体结构。

Crystal structure of a diabody, a bivalent antibody fragment.

作者信息

Perisic O, Webb P A, Holliger P, Winter G, Williams R L

机构信息

Centre for Protein Engineering, MRC Centre, Cambridge, UK.

出版信息

Structure. 1994 Dec 15;2(12):1217-26. doi: 10.1016/s0969-2126(94)00123-5.

DOI:10.1016/s0969-2126(94)00123-5
PMID:7704531
Abstract

BACKGROUND

Diabodies are dimeric antibody fragments. In each polypeptide, a heavy-chain variable domain (VH) is linked to a light-chain variable domain (VL) but unlike single-chain Fv fragments, each antigen-binding site is formed by pairing of one VH and one VL domain from the two different polypeptides. Diabodies thus have two antigen-binding sites, and can be bispecific. Direct structural evidence is lacking for the connections and dimeric interactions between the two polypeptides of the diabody.

RESULTS

The 2.6 A resolution structure has been determined for a bivalent diabody with a flexible five-residue polypeptide linker between the (amino-terminal) VH and (carboxy-terminal) VL domains. The asymmetric unit of the crystal consists of four polypeptides comprising two diabodies; for one of these polypeptides the linker can be traced between the VH and VL domains. Within each diabody the two associated VH and VL domains make back-to-back interactions through the VH domains, and there is an extensive VL-VL interface between the two diabodies in the asymmetric unit.

CONCLUSIONS

The structure of the diabody is very similar to that which had been predicted by molecular modelling. Diabodies directed against cell-surface antigens should be capable of bringing together two cells, such as in cell-targeted therapy, because the two antigen-binding sites of the diabody are at opposite ends of the molecule and separated by approximately 65 A.

摘要

背景

双抗体是二聚体抗体片段。在每条多肽链中,重链可变区(VH)与轻链可变区(VL)相连,但与单链Fv片段不同的是,每个抗原结合位点是由来自两条不同多肽链的一个VH结构域和一个VL结构域配对形成的。因此,双抗体有两个抗原结合位点,并且可以是双特异性的。目前缺乏关于双抗体两条多肽链之间连接和二聚体相互作用的直接结构证据。

结果

已确定了一种二价双抗体的分辨率为2.6 Å的结构,其在(氨基端)VH结构域和(羧基端)VL结构域之间有一个由五个残基组成的柔性多肽接头。晶体的不对称单元由四条多肽链组成,包含两个双抗体;对于其中一条多肽链,可以追踪到VH结构域和VL结构域之间的接头。在每个双抗体中,两个相关的VH和VL结构域通过VH结构域进行背对背相互作用,并且在不对称单元中的两个双抗体之间存在广泛的VL-VL界面。

结论

双抗体的结构与分子建模预测的结构非常相似。针对细胞表面抗原的双抗体应该能够使两个细胞聚集在一起,例如在细胞靶向治疗中,因为双抗体的两个抗原结合位点位于分子的相对两端,相距约65 Å。

相似文献

1
Crystal structure of a diabody, a bivalent antibody fragment.双价抗体片段双体的晶体结构。
Structure. 1994 Dec 15;2(12):1217-26. doi: 10.1016/s0969-2126(94)00123-5.
2
The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3.具有非同源VH-VL结构域对的三聚体抗体片段的2.0埃分辨率晶体结构显示VH互补决定区3(VH CDR3)发生了重排。
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9637-42. doi: 10.1073/pnas.94.18.9637.
3
"Diabodies": small bivalent and bispecific antibody fragments.“双抗体”:小型双价双特异性抗体片段。
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8. doi: 10.1073/pnas.90.14.6444.
4
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.二价抗ErbB2双抗体片段对肿瘤细胞的靶向作用与抗体的固有亲和力无关。
Cancer Res. 2000 Nov 15;60(22):6434-40.
5
scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies.抗神经氨酸酶抗体NC10的单链抗体片段多聚体:VH和VL结构域之间连接子的长度精确决定双体和三体之间的转变。
Protein Eng. 1999 Jul;12(7):597-604. doi: 10.1093/protein/12.7.597.
6
The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility.以V(L)至V(H)方向由T84.66单链抗体片段组装而成的抗癌胚抗原单链抗体双体的晶体结构:对双体灵活性的影响
J Mol Biol. 2003 Feb 14;326(2):341-51. doi: 10.1016/s0022-2836(02)01428-6.
7
Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.结构域顺序对细菌产生的双特异性单链Fv抗体活性的影响。
J Mol Biol. 2003 Jun 27;330(1):99-111. doi: 10.1016/s0022-2836(03)00526-6.
8
Production and structure of diabodies.双抗体的产生与结构
Structure. 1994 Dec 15;2(12):1121-3. doi: 10.1016/s0969-2126(94)00113-8.
9
Single-chain Fvs.单链抗体片段
FASEB J. 1995 Jan;9(1):73-80. doi: 10.1096/fasebj.9.1.7821762.
10
Three-dimensional structures of single-chain Fv-neuraminidase complexes.单链Fv-神经氨酸酶复合物的三维结构
J Mol Biol. 1998 Jun 19;279(4):901-10. doi: 10.1006/jmbi.1998.1794.

引用本文的文献

1
Cross-linking disulfide bonds govern solution structures of diabodies.交联二硫键控制双抗体的溶液结构。
Proteins. 2023 Sep;91(9):1316-1328. doi: 10.1002/prot.26509. Epub 2023 Jun 28.
2
Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy.单链可变片段:癌症诊断与治疗的最新进展
Cancers (Basel). 2022 Aug 30;14(17):4206. doi: 10.3390/cancers14174206.
3
Evaluation and selection of a lead diabody for interferon-γ PET imaging.针对干扰素-γ PET 成像的先导抗体的评估和选择。
Nucl Med Biol. 2022 Nov-Dec;114-115:162-167. doi: 10.1016/j.nucmedbio.2022.06.001. Epub 2022 Jun 17.
4
Structural arrangement of the VH and VL domains in the COBRA™ T-cell engaging single-chain diabody.COBRA™ T细胞结合单链双抗体中VH和VL结构域的结构排列
Antib Ther. 2021 Dec 16;5(1):1-10. doi: 10.1093/abt/tbab028. eCollection 2022 Jan.
5
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.不依赖抗原的激活增强了4-1BB共刺激的CD22嵌合抗原受体T细胞的疗效。
Nat Med. 2021 May;27(5):842-850. doi: 10.1038/s41591-021-01326-5. Epub 2021 Apr 22.
6
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.一刀切并不适合所有人:在多维空间中导航,以优化 T 细胞结合蛋白治疗药物。
MAbs. 2021 Jan-Dec;13(1):1871171. doi: 10.1080/19420862.2020.1871171.
7
A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice.一种针对连接蛋白半通道的有效拮抗剂抗体可减轻突变小鼠的 Clouston 综合征症状。
EBioMedicine. 2020 Jul;57:102825. doi: 10.1016/j.ebiom.2020.102825. Epub 2020 Jun 15.
8
Small molecule AX-024 reduces T cell proliferation independently of CD3ϵ/Nck1 interaction, which is governed by a domain swap in the Nck1-SH3.1 domain.小分子 AX-024 通过 Nck1-SH3.1 结构域的结构域交换来独立于 CD3ϵ/Nck1 相互作用来减少 T 细胞增殖。
J Biol Chem. 2020 Jun 5;295(23):7849-7864. doi: 10.1074/jbc.RA120.012788. Epub 2020 Apr 21.
9
Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach.化学交联双特异性抗体在癌症治疗中的应用:突破遗传融合方法的结构限制。
Int J Mol Sci. 2020 Jan 21;21(3):711. doi: 10.3390/ijms21030711.
10
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.PF-06671008的研发,一种高效的抗P-钙黏蛋白/抗CD3双特异性DART分子,具有延长的半衰期用于癌症治疗。
Antibodies (Basel). 2016 Mar 4;5(1):6. doi: 10.3390/antib5010006.